Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Expected to Announce Earnings of -$1.68 Per Share

Wall Street analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to post ($1.68) earnings per share for the current fiscal quarter, according to Zacks. Eight analysts have made estimates for Ultragenyx Pharmaceutical’s earnings, with the lowest EPS estimate coming in at ($1.97) and the highest estimate coming in at ($1.49). Ultragenyx Pharmaceutical reported earnings of ($1.74) per share during the same quarter last year, which would indicate a positive year over year growth rate of 3.4%. The business is expected to issue its next earnings report on Monday, November 4th.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($7.03) per share for the current financial year, with EPS estimates ranging from ($7.67) to ($6.64). For the next fiscal year, analysts expect that the firm will report earnings of ($5.21) per share, with EPS estimates ranging from ($7.36) to ($2.34). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping analysts’ consensus estimates of ($1.73) by $0.01. The company had revenue of $24.15 million for the quarter, compared to analyst estimates of $22.16 million. Ultragenyx Pharmaceutical had a negative return on equity of 49.84% and a negative net margin of 527.49%. The business’s revenue was up 88.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.06) earnings per share.



RARE has been the subject of a number of recent research reports. Cowen restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, August 15th. Leerink Swann restated a “positive” rating and set a $85.00 target price (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 4th. Piper Jaffray Companies set a $75.00 target price on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, September 4th. JPMorgan Chase & Co. restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 4th. Finally, BidaskClub downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $74.23.

Shares of RARE stock traded down $0.59 on Friday, reaching $44.10. 638,385 shares of the stock were exchanged, compared to its average volume of 546,443. The stock has a market cap of $2.59 billion, a PE ratio of -5.97 and a beta of 2.13. Ultragenyx Pharmaceutical has a one year low of $37.44 and a one year high of $90.98. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.32 and a quick ratio of 9.14. The stock has a 50 day moving average price of $55.52 and a 200 day moving average price of $61.61.

In related news, CEO Emil D. Kakkis acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The stock was acquired at an average price of $43.63 per share, for a total transaction of $218,150.00. Following the completion of the acquisition, the chief executive officer now owns 472,479 shares of the company’s stock, valued at approximately $20,614,258.77. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,489 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $63.01, for a total value of $93,821.89. The disclosure for this sale can be found here. Corporate insiders own 7.80% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Ultragenyx Pharmaceutical by 8.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,113 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 242 shares during the last quarter. Atika Capital Management LLC bought a new stake in Ultragenyx Pharmaceutical in the second quarter valued at about $1,778,000. MetLife Investment Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 10.2% in the first quarter. MetLife Investment Advisors LLC now owns 22,296 shares of the biopharmaceutical company’s stock valued at $1,546,000 after purchasing an additional 2,069 shares during the last quarter. Fosun International Ltd increased its holdings in Ultragenyx Pharmaceutical by 17.3% in the second quarter. Fosun International Ltd now owns 54,144 shares of the biopharmaceutical company’s stock valued at $3,360,000 after purchasing an additional 8,000 shares during the last quarter. Finally, Laurion Capital Management LP bought a new stake in Ultragenyx Pharmaceutical in the first quarter valued at about $1,375,000.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

See Also: Using other technical indicators with support levels

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.